Synlogic (SYBX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
12 Nov, 2025Executive summary
The 2025 Annual Meeting will be held virtually on December 15, 2025, with voting on key proposals including director elections, executive compensation, a new equity incentive plan, and auditor ratification.
Only stockholders of record as of October 24, 2025, are eligible to vote, with 11,698,919 shares outstanding.
The Board recommends voting in favor of all proposals on the agenda.
Voting matters and shareholder proposals
Proposals include electing two Class I directors for three-year terms, an advisory vote on executive compensation, approval of the 2025 Equity Incentive Plan, and ratification of KPMG LLP as auditor.
Stockholders may submit proposals for the 2026 meeting between August 4 and September 3, 2026.
Board of directors and corporate governance
The Board consists of four members, all deemed independent, with staggered three-year terms.
Committees include Audit, Compensation, and Nominating & Governance, all with independent members.
The Board separates the roles of Chairman and Principal Executive Officer and emphasizes risk oversight and regular self-evaluation.
Latest events from Synlogic
- Restructured as a shell after discontinuing clinical programs, with sharply reduced expenses and a $1M net loss.SYBX
Q4 202512 Mar 2026 - Biopharma seeks $150M shelf offering after pivoting to strategic alternatives post-trial halt.SYBX
Registration Filing16 Dec 2025 - Amended filing allows flexible securities issuance and updates legal protections for management.SYBX
Registration Filing16 Dec 2025 - Annual Meeting to vote on director, executive pay, and auditor, with strong governance focus.SYBX
Proxy Filing2 Dec 2025 - Net loss narrowed to $2.3M in Q3 2025 amid restructuring and strategic review.SYBX
Q3 202513 Nov 2025 - Losses narrowed sharply after restructuring and trial discontinuation; strategic review ongoing.SYBX
Q2 20257 Aug 2025 - Lead program ended, costs cut, and strategic options under review with $19.4M cash on hand.SYBX
Q3 202413 Jun 2025 - Q2 net income reached $2.0M after restructuring; $20M cash remains as strategic options are explored.SYBX
Q2 202413 Jun 2025 - Discontinued lead program, restructured operations, and now pursuing strategic alternatives.SYBX
Q4 20249 Jun 2025